Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Urinary Bladder Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Leiomyosarcoma 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Mesothelioma, Malignant 1 Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Endometrioid 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 toripalimab 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 seviteronel 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × rucaparib × Clear all

NCT04276376 2025-12-01

ARIANES

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡